Please login to your online account to display your discounted pricing

anti-Complement 4d, Clone: C4D204, Novus Biologicals™

$321.00 - $429.00

Specifications

Clone C4D204
Host Species Mouse
Isotype IgG1
Immunogen A recombinant protein fragment specific to Complement 4d was used as the immunogen for the antibody.
Antigen Complement 4d
View More Specs

 Disclaimers

For Research Use Only

Products
Catalog Number Mfr. No. Conjugate Quantity Price Quantity    

NBP225234

 
novus biologicals canada
NBP225234
Unlabeled 0.5mL Each for $321.00

NBP2252341M

 
novus biologicals canada
NBP2252341ML
Unlabeled 1mL Each for $429.00
Description & Specifications

Specifications

Clone C4D204
Host Species Mouse
Isotype IgG1
Immunogen A recombinant protein fragment specific to Complement 4d was used as the immunogen for the antibody.
Antigen Complement 4d
Monoclonal or Polyclonal Monoclonal
Format Concentrated
Primary or Secondary Primary
Regulatory Status RUO
Applications Immunohistochemistry (Paraffin)
Test Specificity This antibody is specific to Complement4d (C4d) and it reacts with the secreted as well as cell-bound C4d protein. C4d is a degradation product of the activated complement factor C4b. Complement 4d is typically initiated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of AR that may serve to warrant prompt and aggressive anti-rejection treatment.
Gene Accession No. NP_001239133
Formulation Culture Medium